scholarly journals Cytomegalovirus Viral Load Kinetics and Outcomes in Hematopoietic Stem Cell Transplantation

2018 ◽  
Vol 24 (3) ◽  
pp. S390-S391
Author(s):  
Brandon Webb ◽  
Daanish Hoda
Keyword(s):  
Stem Cell ◽  
Viral Load ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem

HHV-6 Reactivation after Hematopoietic Stem Cell Transplantation in Chinese Patients Is Associated with aGVHD.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4995-4995
Author(s):  
Xiu Jing Ye ◽  
Wei Wei Liao ◽  
Jing Song He ◽  
He Huang
Keyword(s):  
Stem Cell ◽  
Viral Load ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Cumulative Incidence ◽  
Significant Risk ◽  
Chinese Patients ◽  
Hematopoietic Stem

Abstract Recent reports indicate that human herpesvirus (HHV)-6 reactivation occurs in 40–65% of patients undergoing hematopoietic stem cell transplantation (HSCT).But the complication after HSCT that predispose to HHV-6 viremia are not well characterized. The aim of our research is to study the potential relationship between HHV-6 activation and acute graft-versus-host disease (aGVHD) after hematopoietic cell transplantation (HSCT) in chinese patients. Peripheral blood samples were collected before and weekly after HSCT from 40 consecutive recipients who underwent HSCT between March 2005 and Joungry 2007 (2 autologous and 38 allogeneic transplants) .HHV-6 DNAemia was monitored by real-time PCR. The genotypes of HHV-6 were identified by Hind III restriction assay. Of the 40 patients, HHV-6 DNAemia were detected in only 1 patient (2.5%) before HSCT, and the viral load was 420 copies/ml.After HSCT there were 18(45%) patients detected HHV-6 DNA on a median of day 14.5 (range, 0– 23 days), and the median HHV-6 viral load of 4884.4±374.4 copies/ml (range, 282 – 43400 copies/ml). Respectively, HHV-6B was identified as the predominant variant.Grade I – IV aGHVD occurred in 18 (45%) on a median of day 20 (range, 8–40 days). The median onset time of HHV-6 DNAemia was significantly earlier than that of aGHVD (P <0.05). Compared with that in HHV-6 DNAemia positive [HHV-6(+)] patients, the cumulative incidence of grade I – IV aGHVD was higher (72.2% vs. 27.7%, P <0.05) than in negative [HHV-6(−)] patients. Cumulative incidence of grade I – IV aGVHD was higher in patients with both HHV-6 and CMV positive (CMV+/HHV-6+) than in those with either CMV (CMV+/HHV-6−) or HHV-6 positive (CMV−/HHV-6+) and neither of them positive (CMV−/HHV-6−) [66.7% (10/15),26.7% (4/15) ,66.7% (2/3) and 28.6% (2/7), respectively, P<0.05]. Our data suggest that patients who undergo HSCT are at significant risk for HHV-6 reactivation. HHV-6 viremia occurs early during the post-transplant course, most often within the first 2 weeks. Patients with HHV-6 activation or HHV-6/CMV co-infection maybe involved in the occurrence of aGVHD after HSCT.

Chromosomally Integrated HHV-6: Slow Decrease of HHV-6 Viral Load After Hematopoietic Stem-Cell Transplantation

2009 ◽  
Vol 88 (9) ◽  
pp. 1142-1143 ◽  
Author(s):  
Hélène Jeulin ◽  
Matthieu Guéry ◽  
Laurence Clément ◽  
Alexandra Salmon ◽  
Mylène Beri ◽  
...  
Keyword(s):  
Stem Cell ◽  
Viral Load ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Slow Decrease

Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy

2016 ◽  
Vol 18 (6) ◽  
pp. 889-895 ◽  
Author(s):  
Mihaja Raberahona ◽  
Chloe Wackenheim ◽  
Raphaele Germi ◽  
Martin Carré ◽  
Claude-Eric Bulabois ◽  
...  
Keyword(s):  
Stem Cell ◽  
Viral Load ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Epstein Barr

scholarly journals HUMAN HERPES VIRUS TYPE 6 INFECTION IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REPUBLIC OF BELARUS

2020 ◽  
pp. 409-418
Author(s):  
E.P. KISHKURNO ◽  
◽  
T.V. AMVROSIEVA ◽  
YU.E. MAREYKO ◽  
E.V. DIVAKOVA ◽  
...  
Keyword(s):  
Stem Cell ◽  
Viral Load ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Blood Serum ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Clinical Manifestations ◽  
Hematopoietic Stem ◽  
The Republic

Objective: To evaluate the frequency of reactivation of HHV-6 infection in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT); determine viral load in serum/plasma and associated clinical manifestations; to determine the criteria for initiating anti-viral prophylaxis and etiotropic therapy in patients with this infection in the Republic of Belarus. Methods: Monitoring of polymerase chain reaction (PCR) of blood serum in 42 patients after allo-HSCT. Results: In 31% of patients, HHV-6 DNA was detected in serum/plasma on 14-28 days after allo-HSCT. The concentration of HHV-6 DNA in blood serum was up to 2.3-6.5×103 copies/ml, in 3 patients (18.8%) with the concentration of DNA≥2.3×103 copies/ml, developed clinical manifestations in the form of hepatitis. Regular monitoring of HHV-6 infection revealed reactivation of the infection and, with a viral load of≥100 copies/ml, initiate timely preventive treatment with ganciclovir. Conclusions: HHV-6 DNA is detected in one-third of patients after allo-HSCT and in the form of hepatitis. Timely prevention and therapy with ganciclovir reduce the risk of severe complications and fatal outcomes. Keywords: Children, HHV-6, hematology, stem cells transplantation, hepatitis.

scholarly journals How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Blood ◽  
2020 ◽  
Vol 135 (19) ◽  
pp. 1619-1629 ◽  
Author(s):  
Hermann Einsele ◽  
Per Ljungman ◽  
Michael Boeckh
Keyword(s):  
Stem Cell ◽  
Viral Load ◽  
T Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Cmv Disease ◽  
Cmv Reactivation

Abstract Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening infectious complications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technologies, several novel prophylactic agents, and further improvements in preemptive therapy and treatment of established CMV disease. Treatment decisions for CMV reactivation are becoming increasingly difficult and must take into account whether the patient has received antiviral prophylaxis, the patient’s individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV viral load, and the potential drug resistance detected at the time of initiation of antiviral therapy. Thus, we increasingly use personalized treatment strategies for the recipient of an allograft with CMV reactivation based on prior use of anti-CMV prophylaxis, viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resistance to antiviral drugs.

Sign in / Sign up

Export Citation Format

Share Document